Special Issue

Prostate Cancer: Past, Present, and Future

Message from the Guest Editor

This Special Issue of the Cancers (2017 Impact Factor: 5.326) will cover all aspects of prostate cancer, which is the most common non-cutaneous malignancy among men, with nearly 1.3 million new cases diagnosed globally in 2018. This Special Issue intends to publish emerging data, expert opinions, and reviews to add to the growing knowledge base, and to derive meaningful interpretations from available research and clinical insights in scientific literature. A broad range of studies on prostate cancer (research, clinical, outreach, and public health) will be considered for inclusion in this Special Issue. We encourage you to submit original, empirical studies as well as systematic reviews or metaanalyses. Short reports and methodological papers will also be considered. Especially, we encourage the submission of interdisciplinary work and multi-country collaborative research. Keywords

- Prostate cancer
- Cancer health disparities
- Molecular pathogenesis
- Tumor microenvironment
- Prevention and control
- Biomarkers
- Treatments

Guest Editor

Prof. Dr. Ajay Pratap Singh

Cancer Biology Program, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA

Deadline for manuscript submissions

closed (15 November 2019)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/25111

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

